Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Fumarate hydratase (FH) mutated papillary renal cell carcinoma is an aggressive variant of kidney cancer that poorly responds to conventional targeted therapies and immunotherapy. Here, we present the 10-year follow-up of a heavily pre-treated patient with several lines of therapy, achieving a ...
“Based on these data, casdatifan has the potential to be a future treatment option for kidney cancer," says Toni K. Choueiri, MD.
The present study investigated the Zinc finger BED-type containing 3 (ZBED3) mRNA expression levels, diagnostic and prognostic values, co-expressed and differentially expressed genes, immune infiltration, and functional enrichment analysis in patients with kidney renal clear cell carcinoma ...
Clear cell renal cell carcinoma (ccRCC) is a common genitourinary malignancy characterized by dysregulated cellular metabolism leading to aberrant glucose metabolism, fatty acid accumulation, and excessive reactive oxygen species production. ccRCC cells exhibit an augmented oxidative stress ...
David A. Braun, MD, PhD, discusses advancements in biomarker development that could help guide treatment decisions in renal cell carcinoma.
Ami Umesh Badami, MD, discusses a case study illustrating key decisions in the treatment of metastatic renal cell carcinoma.
The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.
Regenerative Medicine Advanced Therapy designation was granted to an investigational CAR-T cell therapy for some patients with renal cell carcinoma.
Alan Tan, MD, discusses the potential role of nivolumab plus ipilimumab in favorable-risk renal cell carcinoma
The RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.